Vimovo. Vimovo has been approved by FDA. Vimovo information

Vimovo. Vimovo has been approved by FDA. Vimovo information

Recently Food and Medicines Administration USA approved Vimovo containing naproxen and esomeprasol for treating patients with arthritis with increased risk if NSAID-associated gastric ulcers. Vimovo is used to relieve symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, as well as to reduce the risk of stomach ulcers in patients with high risk of developing NSAID-associated ulcers. The medication contains two active ingredients – naproxen. Naproxen is a painkiller that belongs to a group of medicines called NSAID’s. The second component of Vimovo is esomeprasole that is immediate release proton pump inhibitor. Esomeprasole works by inhibiting the production of gastric acid for the stomach. FDA decision is based on the results of the clinical trials showed a significant reduction in the incidence of gastric ulcers compared with naproxen in monotherapy (4% vs. 23%).
The most common Vimovo side effects include indigestion, diarrhea, abdominal pain and nausea.


An analyst from a Swiss bank «UBS AG» Gbola Amous (Gbola Amusa) predicts that sales of Vimovo will reach 500 millions of US dollars in 2014 year.

 
According to the terms of license agreement between Astra Zeneca and Prozen, Astra Zeneca will pay nearly 20 millions US dollars to Prozen after Vimovo approval by FDA. In addition, Prozen will get royalties from sales of this product.



Feb 22, 2014